==== Front Sci Rep Sci Rep Scientific Reports 2045-2322 Nature Publishing Group UK London 78333 10.1038/s41598-020-78333-y Article A study of red blood cell alloimmunization and autoimmunization among 200 multitransfused Egyptian β thalassemia patients El-Beshlawy Amal 1 Salama Alshymaa Ahmed 2 El-Masry Mohamed Roshdy 3 El Husseiny Noha M. 34 Abdelhameed Asmaa M. asmaa.mohamed@kasralainy.edu.eg 34 1 grid.7776.10000 0004 0639 9286Department of Pediatric Haematology, Faculty of Medicine, Cairo University, Cairo, Egypt 2 Department of Blood Bank, El-Sahel Teaching Hospital, Cairo, Egypt 3 grid.7776.10000 0004 0639 9286Department of Internal Medicine and Clinical Haematology, Faculty of Medicine, Cairo University, Cairo, Egypt 4 Armed Forces College of Medicine (AFCM), Cairo, Egypt 3 12 2020 3 12 2020 2020 10 2107926 7 2020 24 9 2020 © The Author(s) 2020Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.The development of hemolytic erythrocyte alloantibodies and autoantibodies complicates transfusion therapy in thalassemia patients. These antibodies ultimately increase the need for blood and intensify transfusion complications. There is a scanty data on the frequency of RBC alloimmunization and autoimmunization in Egyptian β thalassemia patients as pretransfusion antibody screening is not routinely performed. We studied the frequency of alloimmunization and autoimmunization among 200 multiply transfused β thalassemia patients and investigated the factors that possibly affect antibody formation. Of the 200 patients in our study, 94 were males and 106 females, with the age range of 2–37 years. Alloantibodies were detected in 36 (18%) of the patients, while autoantibodies were detected in 33 (16.5%). The dominant alloantibodies were directed against Kell (33%) and Rh (24.4%) groups. Alloimmunization had a significant relationship with treatment duration and the frequency of transfusion (P = 0.007, 0.001, respectively). The presence of autoantibodies was significantly related to age (P = 0.001), total number of transfused units (P = 0.000) and splenectomy (P = 0.000). The high prevalence of alloimmunization in the study population disclosed the need for providing phenotypically matched cells for selective antigens especially for Kell and Rh subgroups to reduce risk of alloimmunization and increase the efficiency of blood transfusion. Subject terms DiseasesMedical researchissue-copyright-statement© The Author(s) 2020 ==== Body Introduction Beta-thalassemia is among the most common autosomal recessive genetic disorders worldwide. Despite lack of reliable data for many regions of the world, globally, the estimated carrier rate is about 1.5%1, prevalence is ~ 288,000, and annual incidence of symptomatic individuals is 1 in 100,0002. The burden of the disease is high in the Mediterranean basin and parts of Africa, throughout the Middle East, the Indian subcontinent, and Southeast Asia3. In Egypt, due to consanguineous marriage, the carrier rate is high, reported between 5.3 and ≥ 9%; with the annual incidence of the disease estimated to be 1000/1.5 million live births per year, making β thalassemia a significant health problem in Egypt4. Although allogeneic hematopoietic stem cell transplantation (HSCT) is the only treatment with curative potential, few patients are considered for this treatment, due to lack of suitable donors, restrictions in eligibility requirements, and risk of transplant related mortality5. Appropriate and regular red cell transfusion remains the mainstay of treatment for severe forms of thalassemia; yet, its beneficial effects are limited by transfusion related problems such as viral infections, hemosiderosis and immunization against RBC antigens. Alloimmunization to red cell antigens is a significant clinical challenge in the management of thalassemic patients who would otherwise benefit from transfusions. Alloantibodies may complicate the process of obtaining a suitable crossmatch compatible blood and decrease posttransfusion survival of RBCs. The concomitant presence of autoantibodies may further complicate these hazards. The formation of alloantibodies is a common condition with variable prevalence ranging from 5.2 to 37% according to different studies6–14. The risk of alloantibody formation is influenced by genetic predisposition15, immune modulating conditions as infection16, and the number of transfused units17. Extended matching would be a definitive solution for alloimmunization; however, the required costs and logistics bring up serious concerns in limited resources countries. A more practical and affordable approach is to apply partial better matching (PBM) for the most prevalent antigens. Considering the adverse effects of alloimmunization and autoimmunization and challenges in their management, we conducted this study to evaluate the frequency of erythrocyte alloantibodies and autoantibodies, and specify the most frequent alloantibodies. The ultimate goal is to support the future consideration of applying partial better matching of the major culprit antigens responsible for alloimmunization in Egyptian multiply transfused β-thalassemia patients. Results Patient characteristics Our study comprised a total of 200 patients including 94 males and 106 females. Their ages ranged from 2 to 37 years. The demographic and clinical characteristics of the study population are shown in Table 1. The ABO blood groups were in order of frequency: A (39.5%), B (22.5%), O (27%), and AB (11%). The RhD antigen was negative in 3.5% of the patients (Table 2).Table 1 Demographic and clinical characteristics of the study population. Variable Number Percent Gender Male 94 47.0 Female 106 53.0 Age < 12 years 64 32.0 12–18 years 64 32.0 > 18 years 72 36.0 Diagnosis Thalassemia major 148 74.0 Thalassemia intermedia 52 26.0 Age at start of transfusion < 1 year 90 45.5 1–10 years 104 52.5 > 10 years 9 2.0 Spleen state Splenectomized 118 59.0 Non splenectomized 82 41.0 Table 2 ABO blood groups and RH type distribution. Blood group Number (percent) Rh type Positive Negative A 79 (39.5%) 76 3 B 45 (22.5%) 43 2 O 54 (27%) 53 1 AB 22 (11%) 21 1 Total 200 (100%) 193 (96.7%) 7 (3.5%) Screening and identification of alloantibodies We detected alloantibodies in 36 (18%) patients, the number of alloantibodies per subject ranged from one to three, with the majority, 23 patients (64%), had three alloantibodies, while 10 patients (28%) had two alloantibodies and only 3 patients (8%) had one alloantibody. A total number of 86 alloantibodies were identified, with 12 specificities, the majority (57%) of the antibodies were directed against K antigen and Rh system. Anti K was the most frequent (29; 33.7%), followed by antibodies against Rh antigens (20; 23.2%) [anti-E (7; 8.1%), anti-C (2; 2.3%), anti-Cw (11; 12.8%)]. Anti-Lea was detected in 11.6% (Table 3).Table 3 The number and specificity of alloantibodies in 36 alloimmunized patients. Type of antibody Frequency Number Percent RH Anti-C 2 2.33% Anti-E 7 8.14% Anti-Cʷ 11 12.79% Kell Anti-K 29 33.72% Duffy Anti-Fya 3 3.49% Kidd Anti-Jkb 7 8.14% Lewis Anti-Lea 10 11.63% Anti-Leb 2 2.33% MNS Anti-M 7 8.14% Anti-N 1 1.16% Lutheran Anti-Lua 2 2.33% Anti-Lub 5 5.81% Alloimmunization rate in relation to patients’ characteristics Table 4 summarizes the differences between the alloimmunized and non-alloimmunized patients in relation to the patient related factors deemed to be associated with RBC alloantibody formation. Overall, patients’ gender, diagnosis, age of starting transfusion, total number of blood units transfused, and spleen state did not show statistically significant differences between the alloimmunized and non alloimmunized patients.Table 4 Frequency of alloantibodies in patient’s population in relation to demographic and clinical data. Parameter Alloantibodies P value Present Absent Gender Male 18 (19.1%) 76 (80.9%) 0.477 Female 18 (17.0%) 88 (83.0%) Age < 12 years 8 (12.6%) 56(87.5%) 0.064 12–18 years 8 (12.5%) 56(78.5%) > 18 years 20 (27.8%) 52 (72.2%) Diagnosis Thalassemia major 28 (18.9%) 120 (81.8%) 0.703 Thalassemia intermedia 8 (15.4%) 44 (84.6%) Age of starting transfusion < 1 years 17 (18.9%) 73 (81.1%) 0.873 18 (17.3%) 86 (82.7%) > 10 years 1 (25.0%) 3 (75.0%) Frequency of transfusion units/year < 4/year 2 (15.4%) 11 (84.6%) 0.014 4–12/year 29 (17.7%) 135 (82.3%) > 12/year 5 (21.7%) 18 (78.3%) Transfusion duration in months < 160 m 12 (11.0%) 97 (89.0%) 0.001 ≥ 160 m 24 (26.4%) 67 (73.6%) Splenectomy Splenectomised 25 (21.2%) 93 (78.8%) 0.346 Non splenectomised 11 (13.5%) 71 (86.5%) The prevalence of alloimmunization differed according to the frequency of transfusion per year: 21.7% of patients receiving > 12 units/year were alloimmunized compared to 17.6% of patients receiving from 4 to 12 units/year and 15.3% of patients receiving < 4 units/year (P = 0.014). Alloimmunization was significantly higher in patients with transfusion duration ≥ 160 months 24/91 (26.4%) compared to 12/109 (11%) of patients with transfusion duration < 160 months (P = 0.001). Detection of autoantibodies We detected RBC autoantibodies in 33 (16.5%) of 200 patients; 9 patients (27.2%) were in the alloimmunized group and 24 patients (72.8%) were in the non-alloimmunized group. Table 5 summarizes the differences in frequency of autoantibodies according to patient related factors. Autoimmunization correlated with the patients’ age, autoantibodies could be identified in 19/72 (26.4%) patients > 18 years, compared to 12/64 (18.8%) patients from 12 to 18 years and 2/64 (3.1%) patients < 12 years (P = 0.001). Autoantibody development was also significantly associated with the duration (P = 0.001) and total number (P = 0.000) of transfusion. Splenectomized patients had significantly higher prevalence of autoimmunization (32/118; 27.1%), compared to (1/82; 1.2%) in non splenectomized patients (P = 0.000).Table 5 Frequency of autoantibodies in patient’s population in relation to demographic and clinical data. Parameter Autoantibodies P value Present Absent Gender Male 12 (12.8%) 82 (87.2%) 0.180 Female 21 (19.8%) 85 (80.2%) Age < 12 years 2 (3.1%) 62 (96.9%) 0.001 12–18 years 12 (18.8%) 52 (81.3%) > 18 years 19 (26.4%) 53 (73.6%) Diagnosis Thalassemia major 26 (17.6%) 122 (82.4%) 0.493 Thalassemia intermedia 7 (13.5%) 45 (86.5%) Age of start  < 1 years 15 (16.7%) 75 (83.3%) 0.660 18 (17.3%) 86 (82.7%) > 10 years 0 (0%) 4 (2.4%) Transfusion duration by months < 160 m 9 (8.3%) 100 (91.7%) 0.001 160 m or more 24 (26.4%) 67 (73.6%) Total number of transfusion < 151 8 (7%) 107 (93%) 0.000 151 or more 25 (29.4%) 60 (70.6%) Splenectomy Yes 32 (27.1%) 86 (72.9%) 0.000 No 1 (1.2%) 81 (98.8%) Discussion Regular blood transfusion and iron chelation have dramatically improved life expectancy18 and quality of life for patients with β-thalassemia19. Alloimmunization is one of the most relevant post-transfusion complications as it is associated with transfusion delays, shortened in vivo survival of donor blood, and hemolytic transfusion reactions which can be fatal in some cases20. Recently RBC alloimmunization was identified as an independent predictor of HLA alloimmunization in HSCT with possible clinically significant adverse consequences21. The existence of 35 blood group systems and more than 330 different blood group antigens realistically portray the massive diversity of red blood cell antigens specificities22 and could explain the formation of red cell antibodies. Variable alloimmunization rates were reported in patients with thalassemia. In our study we demonstrated alloimmunization in 36 (18%) patients, which is in concordance with other Egyptian studies23–25 , Obeid et al.; however, found higher frequency of alloantibodies (42.5%) in the studied cohort in Alexandria province, Egypt26. El Danasoury and coworkers investigated the effect of limited donner exposure program (LDEP) on alloimmunization rate, and found alloantibodies in 3% of patients on LDEP compared to 21% of patients receiving transfusion from multiple donners27. Alloimmunization has been linked to antigenic discrepancy between donner and recipients, Singer et al. reported a high alloimmunization rate (20.8%) among Asian patients and concluded that, among other factors, different racial background between white donors from United States and Asian recipients likely contributes to alloimmunization28. An even higher rate (30%) was demonstrated by Ameen and coworkers which was explained by heterogeneity of the population in Kuwait29. Recently, in January 2020, a study in Israel demonstrated 42.5% alloimmunization rate (17 out of 40 patients with transfusion dependent β thalassemia major)30. The burden of RBC alloimmunization is likely underestimated as only a fraction of RBC alloantibodies formed are identified, as a result of peculiar RBC alloantibody induction and evanescence kinetics. Evanescence phenomenon has been found to affect different alloantibodies across antigenic specificities with considerable rates of disappearance31. Quantitation of antibody evanescence have largely focused on hospitalized patients with any diagnosis32,33 and sickle cell disease patients34. It has been estimated that ≈ 30% of induced alloantibodies are regularly detected by antibody screen methods31, this fact underscores the need for complete transfusion records with multiple antibody workups which can be accessed across the health system. Variable antibody specificity had been reported in different studies, attributable to variation in antigen frequency among different populations and the genetic effects on response to this antigenic stimulation. In numerous studies, the antigens of the K and Rh system were predominantly involved in stimulating production of alloantibodies, this predominance is expected considering the immunogenicity of these antigens35. In contrast, antibodies against Milternberger antigens were the most frequently reported in Chinese patients, due to its high prevalence in this population: 15% for Mia antigen and 6–7% for Mur antigen36,37. We identified 12 antibodies specificities, the majority (92%) of patients had more than one alloantibody, with total number of 86 alloantibodies detected in our cohort. Anti K was the most frequent alloantibody detected (33.7%), followed by anti-Cw (12.8%) and anti-Lea (11.6%). Antibodies against Rh antigens collectively constituted 23.2% of alloantibodies detected [anti-E (8.1%), anti-C (2.3%), anti-Cw (12.8%)]. The predominance of Rh and Kell antibodies were previously demonstrated in Kuwaiti, Iranian, Omani, and Tunisian population12,29,38,39. It worth mentioning that the prevalence of K antigen was estimated to be 8.23% among Egyptian blood donors40. Transfusion-related alloimmunization was found to depends mainly on the dose (the extent of transfusions and the absolute number of antigens per RBC) and immunogenicity of the antigen41 as the blood group antigen dose per RBC may vary from only a few to more than a million antigens per RBC42. However, the ability of developing red blood cell alloantibodies found to be restricted to a specific group of blood recipients, whose genetics and inflammation milieu favor the antigen presentation and augment the Th2 response43. Various patient-related factors may also influence the response to these antigens16; therefore, these variables should be explored in attempt to prevent this complex phenomenon. Several studies reported a higher post-transfusion response rate in females, a finding that could not be confirmed in a meta-analysis, by Verduin et al., but was rather attributed to more allogenic exposure mainly because of pregnancy44. In our study, there was no significant difference in alloimmunization rate between males and females. This was also demonstrated by Thompson and colleagues when they assessed 697 patients with thalassemia on regular transfusion9. In 1986, a study by Floss and coworkers demonstrated that infants do not produce alloantibodies even on exposure to many red and white cell antigens45. Later on, several studies showed significantly lower alloimmunization rate in patients who started transfusion therapy early11,28, this observation could be attributed to some form of acquired immune tolerance to red cell alloantigens46. Our study as well as others’ could not confirm this finding47–50; Pahuja et al. found immunization rate of 30% in patients who started transfusion before 1 year7. Numerous studies showed higher alloimmunization rate in splenectomized than nonsplenectomized patients27,28,51,52. This difference proposed to be due to conformational changes in the RBC membrane which enhance immunomodulation leading to an increased risk of RBC allosensitization28; however, this finding may just reflect higher transfusion load. In the present study, no significant association was observed between splenectomy and the development of alloantibodies, similar to what had been reported in other studies13,38,53. Autoantibodies formation in thalassemia patients had been previously reported in the literature11,26,28,38,39,49,54. The presence of RBC autoantibodies may interfere with pre-transfusion blood compatibility tests leading to difficulties in obtaining compatible blood and transfusion delay39. Clinically significant autoimmune hemolysis is a rare but potentially life threatening complication of autoimmunization20. We found autoantibodies in 16.5% of patients, autoantibody development was significantly associated with the patients’ age (P = 0.001). It was also related to duration (P = 0.001) and total number (P = 0.000) of transfusion. Splenectomized patients showed significantly higher prevalence of autoantibodies than non splenectomized patients (P = 0.000), this was previously reported by several researchers11,28,55 and supported by the finding of more erythrocyte-bound IgG in splenectomized thalassemia patient56. Our study as well as others’ shed light into the need for strategies to prevent the production of allo and autoantibodies in order to maximize the effect of transfusion and avoid its complication. Blumberg et al. in their work endorsed the hypothesis that leukoreduction of red cell transfusions alters its immunogenic effect in stimulating alloantibodies production against RBC antigens57. However; the role of leukodepletion in preventing erythrocyte alloimmunization and autoimmunization is not yet well confirmed, with various studies reveling contradictory results14,28,57,58. Extended phenotype matching of transfusions considering antigens like Rh Cc Ee, K, Fy and Jk antigens had led to considerable reduction of the alloimmunization incidence in multiply transfused patients28,38,59. Blood transfusion policy for thalassemia patients in Egypt require more efforts to control allo- and autoimmunization, in compliance with the international guidelines of blood transfusion in transfusion dependent thalassemia60, including provision of leukodereduced transfusion that is phenotypically matched for minor antigens with high frequency and proven significance. In addition, a regimen for follow up testing and documentation of alloantibodies in the transfusion records should be considered in attempt to mitigate delayed hemolytic transfusion reactions. Conclusion Immunization to red blood antigens challenge the proper management of thalassemia patients. Alloimmunization and autoimmunization are common among multiply transfused thalassemia patients in Egypt. The most frequent alloantibodies were against Kell, Rh, Lutheran, and Lewis systems. Ideally, application of extended matched phenotyping can prevent alloimmunization; however, it’s financially and logistically demanding in limited resources health services, so adoption of a transfusion policy that provide phenotypically matched blood for the most frequent significant alloantigens (Rh and Kell) may offer a balanced cost-effective alternative to minimize red cell alloimmunization and autoimmunization among patients with thalassemia. Patients and methods Patients This study was conducted in accordance with the code of conduct of research in Egypt and with the 1964 Helsinki Declaration and its later amendments. It was approved by Research Ethical Committee of Cairo university in October 2018. All participants or their parents and/or legal guardians (if under 18 years) gave informed consent to participate in the study. This study included 200 multiply transfused β thalassemia patients, 148 (74%) thalassemia major and 52 (26%) thalassemia intermedia, registered in Abo-Elrish hospital and clinical hematology outpatient clinic, Kasr Alainy school of medicine, Cairo University. The study was conducted in 4 months’ duration from January to April 2019. Clinical and transfusion records of all the patients were reviewed for demographic and clinical data including age, gender, age of initiating transfusion therapy, transfusion frequency, total number of blood units transfused, and status of splenectomy and these data were collected. Patients were grouped according to age into three categories: < 12 years: 64 patients (32%), between 12 and 18 years: 64 patients (32%), and > 18 years: 72 patients (36%). Transfusion protocol All patients were transfused with ABO and Rh (D) compatible, cross-matched, non leukoreduced blood (using CTD as preservative) with the aim to keep target Hb level 9–11.5 g/dl according to institutional transfusion policy. Methods ABO typing was done by Colum agglutination technique (CAT) using Biovue system (Ortho Cassettes and Centrifuge). Antibody screening was done using Ortho Surgiscreen reagent red blood cells which include most of the blood group of clinical significance. First 50 μL were added to each well, then 10 μL of (3–5%) cell suspension of reagent cells and 40 μL serum/plasma were added and the cassette was incubated for 10 min at 37 °C, then centrifuged for 5 min. The results are interpreted according to manufacturer’s instructions. All positive samples were tested to identify the antibody specificity using Ortho RESOLVE panel A&B (11 cell panel in BioVue AHG Polyspecific Cassettes) based on Column Agglutination Technology as previously described by Delaflor-Weiss and Chizhevsky61. Patients’ serum was mixed with saline-suspended RBCs with the addition of low ionic strength saline and incubated at 37 °C degrees for 10 min. Autoantibodies were detected by incubating patient’s own cell with patient’s plasma at 37 °C for 15 min and then centrifuging for 10 min on gel card containing poly specific antihuman globulin (anti IgG + C3d). Statistical methods Data were statistically described in terms of frequencies (number of cases) and percentages and compared using Chi square (χ2) test. Exact test was used instead when the expected frequency is less than 5. p values less than 0.05 was considered statistically significant. All statistical calculations were done using computer program SPSS (Statistical Package for the Social Science; SPSS Inc., Chicago, IL, USA) release 15 for Microsoft Windows (2006). Compliance with ethical standards All methods were done in accordance with the code of conduct of research in Egypt. This study was approved by the research ethical committee of Cairo university. All subjects or their parents and/or legal guardians (if under 18 years) gave written informed consent. Consent for publication Verbal consents from all participants were obtained. Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Acknowledgements We are thankful to all our patients who participated in this study. Author contributions A.E., A.A., A.S. put research idea, A.S. did all laboratory work and collected data, A.A. wrote manuscript, N.E. and M.E. participated in manuscript writing. Data availability All data are available. Competing interests The authors declare no competing interests. ==== Refs References 1. Trust W The population genetics of the haemoglobinopathies * Baillieres Clin. Haematol. 1998 11 1 51 2. Galanello R Origa R Beta-thalassemia Orphanet. J. Rare Dis. 2010 5 11 10.1186/1750-1172-5-11 20492708 3. Kountouris P IthaGenes: An interactive database for haemoglobin variations and epidemiology PLoS ONE 2014 9 e103020 10.1371/journal.pone.0103020 25058394 4. El-Beshlawy, A. & Youssry, I. Prevention of hemoglobinopathies in Egypt. In Hemoglobin vol. 33 (Hemoglobin, 2009). 5. Smiers FJ Krishnamurti L Lucarelli G Hematopoietic stem cell transplantation for hemoglobinopathies: Current practice and emerging trends Pediatr. Clin. N. Am. 2010 57 181 205 10.1016/j.pcl.2010.01.003 6. Chou ST Liem RI Thompson AA Challenges of alloimmunization in patients with haemoglobinopathies Br. J. Haematol. 2012 159 394 404 10.1111/bjh.12061 23034087 7. Pahuja S Pujani M Gupta SK Chandra J Jain M Alloimmunization and red cell autoimmunization in multitransfused thalassemics of Indian origin Hematology 2010 15 174 177 10.1179/102453309X12583347114013 20557678 8. Matteocci A Pierelli L Red blood cell alloimmunization in sickle cell disease and in thalassaemia: Current status, future perspectives and potential role of molecular typing Vox Sang. 2014 106 197 208 10.1111/vox.12086 24117723 9. Thompson AA Red cell alloimmunization in a diverse population of transfused patients with thalassaemia Br. J. Haematol. 2011 153 121 128 10.1111/j.1365-2141.2011.08576.x 21323889 10. Spanos T Red cell alloantibodies in patients with thalassemia Vox Sang. 1990 58 50 55 2316211 11. Dhawan HKHK Alloimmunization and autoimmunization in transfusion dependent thalassemia major patients: Study on 319 patients Asian J. Transfus. Sci. 2014 8 84 10.4103/0973-6247.137438 25161344 12. Azarkeivan A Blood transfusion and alloimmunization in patients with thalassemia: Multicenter study Pediatr. Hematol. Oncol. 2011 28 479 485 10.3109/08880018.2011.568595 21854216 13. Gupta R Singh DK Singh B Rusia U Alloimmunization to red cells in thalassemics: Emerging problem and future strategies Transfus. Apher. Sci. 2011 45 167 170 10.1016/j.transci.2011.07.014 21856231 14. Wang L-YY Alloimmunization among patients with transfusion-dependent thalassemia in Taiwan Transfus. Med. 2006 16 200 203 10.1111/j.1365-3148.2006.00656.x 16764599 15. Noizat-Pirenne F Relative immunogenicity of Fya and K antigens in a Caucasian population, based on HLA class II restriction analysis Transfusion 2006 46 1328 1333 10.1111/j.1537-2995.2006.00900.x 16934068 16. Bauer MP Wiersum-Osselton J Schipperus M Vandenbroucke JP Briët E Clinical predictors of alloimmunization after red blood cell transfusion Transfusion 2007 47 2066 2071 10.1111/j.1537-2995.2007.01433.x 17958536 17. Zalpuri S Red-blood-cell alloimmunization and number of red-blood-cell transfusions Vox Sang. 2012 102 144 149 10.1111/j.1423-0410.2011.01517.x 21729098 18. Davis BA Porter JB Results of long term iron chelation treatment with deferoxamine Adv. Exp. Med. Biol. 2003 509 91 125 10.1007/978-1-4615-0593-8_6 19. Cappellini, M. D., Cohen, A., Porter, J., Taher, A.V. V. Guidelines for the management of transfusion dependent thalassaemia (TDT) 3rd edition. Thalassaemia International Federation (2014). 20. Sigler E Shvidel L Yahalom V Berrebi A Shtalrid M Clinical significance of serologic markers related to red blood cell autoantibodies production after red blood cell transfusion—Severe autoimmune hemolytic anemia occurring after transfusion and alloimmunization: Successful treatment with rituximab Transfusion 2009 49 1370 1374 10.1111/j.1537-2995.2009.02163.x 19374728 21. Belizaire R Red blood cell alloantibodies are associated with increased alloimmunization against human leukocyte antigens Transfusion 2019 59 2256 2263 10.1111/trf.15306 30980544 22. Geoff, D. Human blood groups: Introduction. Hum. Blood Groups 1–10 (2013). 10.1002/9781118493595.ch1. 23. Ahmed AM Red cell alloimmunization and autoantibodies in Egyptian transfusion-dependent thalassaemia patients Arch. Med. Sci. 2010 6 592 598 10.5114/aoms.2010.14473 22371805 24. Saied DA Kaddah AM Badr Eldin RM Mohaseb SS Alloimmunization and erythrocyte autoimmunization in transfusion-dependent egyptian thalassemic patients J. Pediatr. Hematol. Oncol. 2011 33 409 414 10.1097/MPH.0b013e3182208154 21792035 25. Hussein E Desooky N Rihan A Kamal A Predictors of red cell alloimmunization in multitransfused Egyptian patients with β-thalassemia Arch. Pathol. Lab. Med. 2014 138 684 688 10.5858/arpa.2013-0016-OA 24786127 26. Obaid JMAS Abo El-Nazar SYSY Ghanem AMAM El-Hadidi ASAS Mersal BHM Red blood cells alloimmunization and autoimmunization among transfusion-dependent beta-thalassemia patients in Alexandria province, Egypt Transfus. Apher. Sci. 2015 53 52 57 10.1016/j.transci.2015.03.006 25817267 27. El Danasoury AS Eissa DG Abdo RM Elalfy MS Red blood cell alloimmunization in transfusion-dependent Egyptian patients with thalassemia in a limited donor exposure program Transfusion 2012 52 43 47 10.1111/j.1537-2995.2011.03234.x 21745214 28. Singer ST Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent Blood 2000 96 3369 3373 10.1182/blood.V96.10.3369 11071629 29. Ameen R RBC alloimmunization and autoimmunization among transfusion-dependent Arab thalassemia patients Transfusion 2003 43 1604 1610 10.1046/j.1537-2995.2003.00549.x 14617321 30. Pazgal I Yahalom V Shalev B Raanani P Stark P Alloimmunization and autoimmunization in adult transfusion-dependent thalassemia patients: A report from a comprehensive center in Israel Ann. Hematol. 2020 10.1007/s00277-020-04104-4 32488601 31. Tormey CA Hendrickson JE Transfusion-related red blood cell alloantibodies: Induction and consequences Blood 2019 133 1821 1830 10.1182/blood-2018-08-833962 30808636 32. Reverberi, R. The persistence of red cell alloantibodies. In Blood Transfusion vol. 6 225–234 (SIMTI Servizi, 2008). 33. Tormey CA Stack G The persistence and evanescence of blood group alloantibodies in men Transfusion 2009 49 505 512 10.1111/j.1537-2995.2008.02014.x 19040411 34. Nickel RS Immunophenotypic parameters and RBC alloimmunization in children with sickle cell disease on chronic transfusion Am. J. Hematol. 2015 90 1135 1141 10.1002/ajh.24188 26361243 35. Poole J Daniels G Blood group antibodies and their significance in transfusion medicine Transfus. Med. Rev. 2007 21 58 71 10.1016/j.tmrv.2006.08.003 17174221 36. Chao YH Red blood cell alloimmunisation among Chinese patients with β-thalassaemia major in Taiwan Blood Transfus. 2013 11 71 74 22790261 37. Chen Z Prognostic evaluation of immunohistochemical profiles in diffuse large B-cell lymphoma: A Chinese study Med. Oncol. 2011 28 241 248 10.1007/s12032-010-9433-3 20165991 38. Al-Riyami AZ Risks of red blood cell alloimmunization in transfusion-dependent β-thalassemia in Oman: A 25-year experience of a university tertiary care reference center and a literature review Transfusion 2018 58 871 878 10.1111/trf.14508 29399805 39. Guirat-Dhouib N High frequency of autoimmunization among transfusion-dependent Tunisian thalassaemia patients Transfus. Apher. Sci. 2011 45 199 202 10.1016/j.transci.2011.08.003 21889408 40. Abou El-Fetouh, R. M. et al. Prevalence of Red Cell Blood Group Antigens Among Egyptian Population in Comparison with Other Ethnic Groups. Cairo Univ vol. 86 www.medicaljournalofcairouniversity.net (2018). 41. Körmöczi GF Mayr WR Responder individuality in red blood cell alloimmunization Transfus. Med. Hemother. 2014 41 446 451 10.1159/000369179 25670932 42. Daniels, G. Human Blood Groups. Human Blood Groups: 3rd edition (Wiley-Blackwell, Hoboken, 2013). 10.1002/9781118493595. 43. Dinardo CL Red blood cell alloantibodies and autoantibodies: Different presentation, same physiopathology Hematol. Transfus. Cell Ther. 2018 40 99 100 10.1016/j.htct.2017.09.002 30057979 44. Verduin EP Brand A Schonewille H Is female sex a risk factor for red blood cell alloimmunization after transfusion? A systematic review Transfus. Med. Rev. 2012 26 342 353.e5 10.1016/j.tmrv.2011.12.001 22244869 45. Floss AM Strauss RG Goeken N Knox L Multiple transfusions fail to provoke antibodies against blood cell antigens in human infants Transfusion 1986 26 419 422 10.1046/j.1537-2995.1986.26587020115.x 3765033 46. Michail-Merianou V Pamphili-Panousopoulou L Piperi-Lowes L Pelegrinis E Karaklis A Alloimmunization to red cell antigens in thalassemia: Comparative study of usual versus better-match transfusion programmes Vox Sang. 1987 52 95 98 10.1159/000461619 3300026 47. Bhatti F Salamat N Nadeem A Shabbir N Red cell immunization in beta thalassaemia major J. Coll. Phys. Surg. Pak. 2004 14 657 660 48. Gader AGMA Al Ghumlas AK Al-Momen AKM Transfusion medicine in a developing country—alloantibodies to red blood cells in multi-transfused patients in Saudi Arabia Transfus. Apher. Sci. 2008 39 199 204 10.1016/j.transci.2008.09.013 18951063 49. Davari, K. & Soltanpour, M. S. M. S. Study of alloimmunization and autoimmunization in Iranian β-thalassemia major patients. Asian J. Transfus. Sci.10, (2016). 50. Karimi M Nikrooz P Kashef S Jamalian N Davatolhagh Z RBC alloimmunization in blood transfusion-dependent β-thalassemia patients in southern Iran Int. J. Lab. Hematol. 2007 29 321 326 10.1111/j.1365-2257.2006.00856.x 17824911 51. Romphruk AV The prevalence, alloimmunization risk factors, antigenic exposure, and evaluation of antigen-matched red blood cells for thalassemia transfusions: A 10-year experience at a tertiary care hospital Transfusion 2019 59 177 184 10.1111/trf.15002 30443908 52. Abdelrazik AM Study of red blood cell alloimmunization risk factors in multiply transfused thalassemia patients: role in improving thalassemia transfusion practice in Fayoum, Egypt Transfusion 2016 56 2303 2307 10.1111/trf.13695 27351342 53. Ho HK Alloimmunization in Hong Kong Southern Chinese transfusion-dependent thalassemia patients Blood 2001 97 3999 4000 10.1182/blood.V97.12.3999 11405212 54. Jain R Detection and identification of red cell alloantibodies in multiply transfused thalassemia major patients: A prospective study Indian J. Hematol. Blood Transfus. 2014 30 291 296 10.1007/s12288-013-0282-z 25435730 55. Hendrickson JE Tormey CA Red blood cell antibodies in hematology/oncology patients: Interpretation of immunohematologic tests and clinical significance of detected antibodies Hematol. Oncol. Clin. N. Am. 2016 30 635 651 10.1016/j.hoc.2016.01.006 56. Wiener E Erythroblast- and erythrocyte-bound antibodies in α and β thalassaemia syndromes Transfus. Med. 1991 1 229 238 10.1111/j.1365-3148.1991.tb00038.x 9259854 57. Blumberg N Heal JM Gettings KF WBC reduction of RBC transfusions is associated with a decreased incidence of RBC alloimmunization Transfusion 2003 43 945 952 10.1046/j.1537-2995.2003.00443.x 12823755 58. Schonewille H Brand A Alloimmunization to red blood cell antigens after universal leucodepletion. A regional multicentre retrospective study Br. J. Haematol. 2005 129 151 156 10.1111/j.1365-2141.2005.05408.x 15801967 59. Lasalle-Williams M Extended red blood cell antigen matching for transfusions in sickle cell disease: A review of a 14-year experience from a single center (CME) Transfusion 2011 51 1732 1739 10.1111/j.1537-2995.2010.03045.x 21332724 60. Cappellini, M. D., Cohen, A., Porter, J., Taher, A. & Viprakasit, V. Guidelines for the Management of Transfusion Dependant Thalassemia (TDT). 61. Delaflor-Weiss E Chizhevsky V Implementation of gel testing for antibody screening and identification in a community hospital, a 3-year experience Lab. Med. 2005 36 489 492 10.1309/JAP6EC69BAAUG9B3